Active Filter(s):
Details:
With the financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related macular degeneration.
Lead Product(s): CTX001
Therapeutic Area: Ophthalmology Product Name: CTx001
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gimv
Deal Size: $78.9 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 17, 2023